D’Oronzo S, Stucci S, Tucci M, Silvestris F (2015) Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. Cancer Treat Rev 41:798–808

Article  PubMed  Google Scholar 

Diana A, Carlino F, Giunta EF, Franzese E, Guerrera LP, Di Lauro V, Ciardiello F, Daniele B, Orditura M (2021) Cancer treatment-induced bone loss (CTIBL): state of the art and proper management in breast cancer patients on endocrine therapy. Curr Treat Options Oncol 22:45

Article  PubMed  PubMed Central  Google Scholar 

Takahashi S (2023) Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer. J Bone Miner Metab 41:307–316

Article  PubMed  Google Scholar 

Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Vassalli L, Rodella F, Formenti AM (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open 2:e1911080–e1911080

Article  PubMed  PubMed Central  Google Scholar 

Lee YK, Lee EG, Kim HY, Lee Y, Lee SM, Suh DC, Yoo JI, Lee S (2020) Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis. J Korean Med Sci 35:e403

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee S, Yoo JI, Lee YK, Park JW, Won S, Yeom J, Im JW, Lim SM, Ha YC, Koo KH (2020) Risk of osteoporotic fracture in patients with breast cancer: meta-analysis. J Bone Metab 27:27–34

Article  PubMed  PubMed Central  Google Scholar 

Fukumoto S, Soen S, Taguchi T, Ishikawa T, Matsushima H, Terauchi M, Horie S, Yoneda T, Sugimoto T, Matsumoto T, Subcommittee for CTIBL in the JSBMR (2020) Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab 38:141–144

Article  PubMed  Google Scholar 

Khan MI (2023) Management of bone loss due to endocrine therapy during cancer treatment. Osteoporos Int 34:671–680

Article  CAS  PubMed  Google Scholar 

Stevens Z, Hellig J (2022) Breast cancer therapy and bone. Climacteric 25:67–72

Article  CAS  PubMed  Google Scholar 

Mei M, Xiang Z, Yang J, Xiang R (2020) Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: a meta-analysis of 13 randomized controlled trials. Curr Prob Cancer 44:100507

Article  Google Scholar 

Ha J, Lee JM, Lim Y, Kim MK, Kwon HS, Song KH, Jeon HM, Kang MI, Baek KH (2020) Effect of bisphosphonate on the prevention of bone loss in patients with gastric cancer after gastrectomy: a randomized controlled trial. Bone 130:115138

Article  CAS  PubMed  Google Scholar 

Bruyère O, Bergmann P, Cavalier E, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Body JJ (2017) Skeletal health in breast cancer survivors. Maturitas 105:78–82

Article  PubMed  Google Scholar 

Waqas K, Ferreira JL, Tsourdi E, Body JJ, Hadji P, Zillikens MC (2021) Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 28:100355

Article  PubMed  PubMed Central  Google Scholar 

Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C (2020) Bone health in cancer ESMO clinical practice guidelines. Ann Oncol 31:1650–1663

Article  CAS  PubMed  Google Scholar 

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12

Article  PubMed  PubMed Central  Google Scholar 

Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37:2916–2946

Article  PubMed  Google Scholar 

Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D, Coleman R (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. Eur J Cancer 94:70–78

Article  CAS  PubMed  Google Scholar 

Coleman R, De Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, Von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398–405

Article  CAS  PubMed  Google Scholar 

Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133:685–693

Article  CAS  PubMed  Google Scholar 

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

Article  CAS  PubMed  Google Scholar 

Satoh T, Kimura M, Matsumoto K, Tabata KI, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 115:3468–3474

Article  CAS  PubMed  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N (2024) Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22:331–357

Article  PubMed  Google Scholar 

Kang T et al (2022) Comparison of denosumab and zoledronic acid in postmenopausal women with osteoporosis: bone mineral density (BMD) and trabecular bone score (TBS). J Korean Med Sci 37:e68

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brufsky AM et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192–1201

Article  CAS  PubMed  Google Scholar 

Kang T, Park SY, Lee SH, Park JH, Suh SW (2021) Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer. J Bone Miner Metab 39:1031–1040

Article  Google Scholar 

Stumpf U, Kostev K, Siebenbürger G, Böcker W, Hadji P (2020) Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer - a retrospective cohort study. J Bone Oncol 22:100292

Article  PubMed  PubMed Central  Google Scholar 

McCloskey E (2006) Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 42:1044–1051

Article  CAS  PubMed  Google Scholar 

Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21:1215–1223

Article  CAS  PubMed  Google Scholar 

Wang S, Wu W, Lin X, Zhang KM, Wu Q, Luo M, Zhou J (2023) Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions. Cell Biosci 13:224

Article  PubMed  PubMed Central  Google Scholar 

Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K (2018) Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: results from the AZURE (BIG01/04) trial. JNCI: J Natl Cancer Inst 110:871–879

PubMed  PubMed Central